Dual-Action Biologic Lunsekimig Shows Promise in Phase II Asthma Trial
Source Summary
The investigational biologic lunsekimig demonstrated promise in the phase II AIRCULES study for treating moderate-to-severe asthma. The drug uses a dual inflammation blockade mechanism, targeting both thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13.
Why it matters
A successful dual-target biologic could expand treatment options for patients with moderate-to-severe asthma who may not respond adequately to existing therapies.
